LEXICON PHARMACEUTICALS, INC. Finite-Lived Intangible Assets, Accumulated Amortization
LEXICON PHARMACEUTICALS, INC. (LXRX) had Finite-Lived Intangible Assets, Accumulated Amortization of $5.89 million as of 2020-06-30, per its 10-Q filed 2020-07-29.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization › Intangible Asset, Finite-Lived, after Accumulated Amortization
us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization · last filed 2020-07-29
- 2020-06-30: Finite-Lived Intangible Assets, Accumulated Amortization $5.89M.
- 2020-03-31: Finite-Lived Intangible Assets, Accumulated Amortization $5.44M.
- 2019-09-30: Finite-Lived Intangible Assets, Accumulated Amortization $4.56M.
- 2019-06-30: Finite-Lived Intangible Assets, Accumulated Amortization $5.00M; Finite-Lived Intangible Assets, Accumulated Amortization as first filed $4.12M.
| Period end | Finite-Lived Intangible Assets, Accumulated Amortization | Finite-Lived Intangible Assets, Accumulated Amortization as first filed |
|---|---|---|
| 2020-06-30 | $5.89M 10-Q · filed 2020-07-29 | |
| 2020-03-31 | $5.44M 10-Q · filed 2020-04-27 | |
| 2019-09-30 | $4.56M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $5.00M 10-Q · filed 2020-07-29 | $4.12M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $5.00M 10-Q · filed 2020-04-27 | $3.68M 10-Q · filed 2019-05-01 |
| 2018-12-31 | $3.24M 10-Q · filed 2019-11-07 | |
| 2018-09-30 | $2.79M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $2.35M 10-Q · filed 2018-07-30 | |
| 2018-03-31 | $1.91M 10-Q · filed 2018-05-03 | |
| 2017-12-31 | $1.47M 10-Q · filed 2018-11-01 | |
| 2017-09-30 | $1.03M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $589.00K 10-Q · filed 2017-08-01 | |
| 2017-03-31 | $147.00K 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $0.00 10-Q · filed 2017-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |